<DOC>
	<DOCNO>NCT00622830</DOCNO>
	<brief_summary>This study conduct provide safety , tolerability , PK PD data repeat dose allow study darapladib Japanese patient</brief_summary>
	<brief_title>Phase I Study SB-480848 ( Darapladib ) -Repeat Dose Study Healthy Japanese Male Subjects-</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Darapladib</mesh_term>
	<criteria>Inclusion criterion : Healthy Japanese adult male 20 64 yea age , inclusive . Healthy subject define individual free clinically significant disease determine medical history , physical examination , clinical laboratory examination , vital sign , 12lead ECG , immunology test urinary drug screen test . Bodyweight &gt; 50 kg body mass index ( BMI ) 18.5 25.0 screening . Subjects must capable provide write informed consent , include compliance requirement restriction list consent form . Baseline QTc interval &lt; 450 msec . Nonsmoker exsmoker cease smoke least 6 month . Clinical laboratory examination ( AST , ALT , ALP GGT ) screen within normal range . The subject able attend visit complete study . Exclusion criterion : Any clinically relevant abnormality identify screen physical examination , vital sign measurement , 12lead ECG record and/or clinical laboratory examination deem principal investigator and/or medical monitor make subject ineligible inclusion safety concern . History regular alcohol consumption exceed , average , 14 drinks/week men ( 1 drink = 5 ounce ( 150 mL ) wine 350 mL beer 1.5 ounce ( 45 mL ) 80 proof distil spirit ) within 6 month screen . Positive urine drug screening . Positive syphilis , HIV antibody , Hepatitis B surface antigen , Hepatitis C antibody HTLV1 antibody screen . Use prescription noprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day 5 halflives ( whichever longer ) prior first dose study medication . Consumption grapefruit juice food within 7 day prior first dose study medication . A history cholecystectomy biliary tract disease include history liver disease elevate liver function test know unknown etiology . Donation blood excess 400mL within 4 month 200mL within 1 month prior screen . History drug abuse , current condition drug abuse alcoholism . Participation clinical study postmarketing study investigational noninvestigational product device within 4 month precede first dose study medication . Participation another clinical study postmarketing study subject expose investigational noninvestigational product device . History asthma , anaphylaxis anaphylactoid reaction , severe allergic response . The subject allergy drug idiosyncrasy . This exclude pollen allergy without current symptom . History sensitivity heparin heparininduced thrombocytopenia .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>darapladib ,</keyword>
	<keyword>SB480848 ,</keyword>
	<keyword>Japanese healthy volunteer</keyword>
</DOC>